NASDAQ:CTSO - Cytosorbents Stock Price, Price Target & More

$7.50 -0.10 (-1.32 %)

(As of 04/25/2018 03:06 AM ET)

Previous Close$7.60

Today's Range$7.40 - $7.80

52-Week Range$3.30 - $8.35

Volume289,900 shs

Average Volume183,156 shs

Market Capitalization$226.93 million

P/E Ratio-23.44

Dividend YieldN/A

Beta-0.08

About Cytosorbents (NASDAQ:CTSO)

CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. The company also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, it is developing CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, the company is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. It has collaboration with Aferetica srl to develop PerLife ex-vivo organ perfusion system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is headquartered in Monmouth Junction, New Jersey.

Receive CTSO News and Ratings via Email

Sign-up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:CTSO

CUSIPN/A

Webwww.cytosorbents.com

Phone732-329-8885

Debt

Debt-to-Equity Ratio0.58%

Current Ratio2.64%

Quick Ratio2.54%

Price-To-Earnings

Trailing P/E Ratio-23.44

Forward P/E Ratio-15.96

P/E GrowthN/A

Sales & Book Value

Annual Sales$15.15 million

Price / Sales14.59

Cash FlowN/A

Price / CashN/A

Book Value$0.36 per share

Price / Book20.83

Profitability

EPS (Most Recent Fiscal Year)($0.32)

Net Income$-8,460,000.00

Net Margins-52.08%

Return on Equity-118.07%

Return on Assets-40.15%

Miscellaneous

Employees84

Outstanding Shares29,470,000

How to Become a New Pot Stock Millionaire

Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions

What is Cytosorbents' stock symbol?

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

How were Cytosorbents' earnings last quarter?

Cytosorbents Co. (NASDAQ:CTSO) announced its earnings results on Thursday, March, 8th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.02. The medical research company had revenue of $4.65 million for the quarter, compared to analyst estimates of $4.56 million. Cytosorbents had a negative return on equity of 118.07% and a negative net margin of 52.08%. View Cytosorbents' Earnings History.

When is Cytosorbents' next earnings date?

Cytosorbents is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Cytosorbents.

What price target have analysts set for CTSO?

5 brokerages have issued 1-year target prices for Cytosorbents' stock. Their predictions range from $9.00 to $14.00. On average, they anticipate Cytosorbents' share price to reach $11.05 in the next twelve months. View Analyst Ratings for Cytosorbents.

Who are some of Cytosorbents' key competitors?

Some companies that are related to Cytosorbents include K2M Group (KTWO), MiMedx Group (MDXG), LeMaitre Vascular (LMAT), CryoLife (CRY), Cardiovascular Systems (CSII), AtriCure (ATRC), AngioDynamics (ANGO), Cerus (CERS), Anika Therapeutics (ANIK), Tactile Systems Technology (TCMD), SurModics (SRDX), Accuray (ARAY), Inovio Pharmaceuticals (INO), Utah Medical Products (UTMD) and Endologix (ELGX).

Who are Cytosorbents' key executives?

Cytosorbents' management team includes the folowing people:

Dr. Phillip P. Chan M.D., Ph.D., CEO, Pres & Director (Age 48)
Ms. Kathleen P. Bloch MBA, CPA, CFO & Sec. (Age 63)
Mr. Vincent J. Capponi MS, Chief Operating Officer (Age 60)
Dr. Robert H. Bartlett M.D., Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 79)
Dr. Christian Steiner M.D., VP of Sales & Marketing

Has Cytosorbents been receiving favorable news coverage?

Headlines about CTSO stock have trended positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cytosorbents earned a media sentiment score of 0.35 on Accern's scale. They also gave media coverage about the medical research company an impact score of 48.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Cytosorbents?

Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytosorbents' stock price today?

One share of CTSO stock can currently be purchased for approximately $7.50.

How big of a company is Cytosorbents?

Cytosorbents has a market capitalization of $226.93 million and generates $15.15 million in revenue each year. The medical research company earns $-8,460,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Cytosorbents employs 84 workers across the globe.

How can I contact Cytosorbents?

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected]

MarketBeat Community Rating for Cytosorbents (CTSO)

Community Ranking:		3.8 out of 5 ( )
Outperform Votes:		268 (Vote Outperform)
Underperform Votes:		88 (Vote Underperform)
Total Votes:		356

MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote "Outperform" if you believe CTSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTSO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Cytosorbents (NASDAQ:CTSO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

5 Wall Street analysts have issued ratings and price targets for Cytosorbents in the last 12 months. Their average twelve-month price target is $11.05, suggesting that the stock has a possible upside of 47.33%. The high price target for CTSO is $14.00 and the low price target for CTSO is $9.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$11.05	$11.05	$10.65	$10.45
Price Target Upside:	47.33% upside	39.87% upside	37.95% upside	72.73% upside

Cytosorbents (NASDAQ:CTSO) Consensus Price Target History

Price Target History for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ:CTSO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/24/2018	Maxim Group	Set Price Target	Buy	$12.00	High
3/9/2018	HC Wainwright	Set Price Target	Buy	$14.00	Medium
3/8/2018	Cowen	Set Price Target	Buy	$9.00	Medium
1/25/2018	B. Riley	Reiterated Rating	Buy	$11.25	Low
7/25/2017	Aegis	Reiterated Rating	Buy	$9.00	High
10/4/2016	Brean Capital	Initiated Coverage	Buy	$24.00	N/A

(Data available from 4/25/2016 forward)

Cytosorbents (NASDAQ:CTSO) Earnings History and Estimates Chart

Earnings by Quarter for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ:CTSO) Earnings Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.09)	($0.09)	($0.09)
Q2 2018	1	($0.11)	($0.11)	($0.11)

Cytosorbents (NASDAQ CTSO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018							N/A
3/8/2018	Q4 2017	($0.10)	($0.12)	$4.56 million	$4.65 million	View	N/A
11/9/2017	Q3 2017	($0.07)	($0.07)	$3.67 million	$3.45 million	View	N/A
8/7/2017	Q2 2017	($0.06)	($0.04)	$3.29 million	$3.57 million	View	Listen
5/8/2017	Q1 2017	($0.11)	($0.05)	$2.99 million	$3.11 million	View	Listen
3/3/2017	Q4 2016	($0.10)	($0.16)	$2.59 million	$3.08 million	View	N/A
11/7/2016	Q3	($0.11)	($0.11)	$2.35 million	$2.14 million	View	Listen
8/9/2016	Q216	($0.09)	($0.12)	$2.18 million	$1.90 million	View	N/A
5/9/2016	Q116	($0.10)	($0.08)	$1.73 million	$1.80 million	View	N/A
3/9/2016	Q415	($0.08)	($0.08)	$1.51 million	$1.76 million	View	N/A
11/13/2015	Q315	($0.10)	($0.11)	$1.26 million	$1.30 million	View	Listen
8/13/2015	Q215	($0.11)	$0.05	$0.92 million	$0.96 million	View	Listen
5/11/2015	Q115	($0.13)	($0.11)	$0.80 million	$0.72 million	View	Listen
11/12/2014	Q3 2014	($0.25)	($0.25)	$1.28 million	$1.16 million	View	N/A
8/12/2014	Q2 2014	($0.01)	($0.01)	$1.13 million	$1.03 million	View	N/A
5/14/2014	Q1 2014	($0.25)	($0.25)	$1.02 million	$1.06 million	View	N/A
3/31/2014	Q4 2013	($0.01)	($0.01)	$8.34 million	$0.88 million	View	N/A
11/6/2013	Q3 2013	($0.25)	($0.25)	$0.70 million	$0.88 million	View	N/A
8/14/2013	Q2 2013	($0.25)	($0.25)		$0.29 million	View	N/A
5/16/2013	Q1 2013		($0.25)	$0.85 million	$0.37 million	View	N/A
4/3/2013	Q4 2012		($0.25)			View	N/A
11/21/2012	Q3 2012	($0.25)	($0.25)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Cytosorbents (NASDAQ:CTSO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Cytosorbents (NASDAQ CTSO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 10.85%

Insider Trading History for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ CTSO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/17/2018	Kathleen P Bloch	CFO	Sell	120	$8.25	$990.00	253,424
3/15/2018	Kathleen P Bloch	CFO	Sell	11,176	$8.25	$92,202.00	261,246
3/13/2018	Kathleen P Bloch	CFO	Sell	1,104	$8.25	$9,108.00	251,174
2/21/2018	Kathleen P Bloch	CFO	Sell	10,000	$8.00	$80,000.00	268,870
1/12/2018	Kathleen P Bloch	CFO	Sell	12,400	$7.75	$96,100.00	241,038
1/8/2018	Kathleen P Bloch	CFO	Sell	32,400	$7.30	$236,520.00	248,638
11/27/2017	Vincent Capponi	COO	Sell	4,000	$7.00	$28,000.00	271,062
6/9/2017	Eric R Mortensen	Insider	Buy	2,500	$4.04	$10,100.00	2,500
6/9/2017	Michael G. Bator	Director	Buy	1,500	$4.12	$6,180.00
6/8/2017	Phillip P. Chan	Insider	Buy	3,700	$4.00	$14,800.00
6/8/2017	Vincent Capponi	COO	Buy	2,500	$4.00	$10,000.00
6/5/2017	Phillip P. Chan	Insider	Buy	6,300	$4.00	$25,200.00
5/15/2017	Kathleen P. Bloch	CFO	Buy	1,000	$4.34	$4,340.00
12/9/2016	Phillip P. Chan	Insider	Buy	4,600	$5.40	$24,840.00
12/6/2016	Kathleen P Bloch	CFO	Buy	1,000	$4.83	$4,830.00	122,325
8/24/2016	Phillip P Chan	Insider	Buy	5,000	$4.89	$24,450.00	121,648
6/7/2016	Michael G Bator	Director	Buy	3,000	$4.88	$14,640.00	3,000
10/29/2015	Vincent Capponi	COO	Sell	4,000	$7.50	$30,000.00	16,724
10/15/2015	Al Kraus	Director	Sell	6,774	$6.22	$42,134.28	55,746
10/8/2015	Al Kraus	Director	Sell	10,000	$6.39	$63,900.00	55,746
10/1/2015	Al Kraus	Director	Sell	10,000	$6.26	$62,600.00	55,746
9/24/2015	Al Kraus	Director	Sell	10,000	$6.44	$64,400.00	55,746
9/17/2015	Al Kraus	Director	Sell	10,000	$6.64	$66,400.00	55,746
9/10/2015	Al Kraus	Director	Sell	10,000	$7.26	$72,600.00	55,746
9/3/2015	Al Kraus	Director	Sell	10,000	$7.26	$72,600.00	55,746
8/27/2015	Al Kraus	Director	Sell	10,000	$6.39	$63,900.00	55,746
8/20/2015	Al Kraus	Director	Sell	10,000	$7.26	$72,600.00	55,746
8/13/2015	Al Kraus	Director	Sell	10,000	$6.26	$62,600.00
7/23/2015	Al Kraus	Director	Sell	10,000	$6.28	$62,800.00
7/16/2015	Al Kraus	Director	Sell	10,000	$6.33	$63,300.00
7/9/2015	Al Kraus	Director	Sell	10,000	$5.98	$59,800.00
7/2/2015	Al Kraus	Director	Sell	10,000	$6.29	$62,900.00
6/25/2015	Al Kraus	Director	Sell	13,205	$7.33	$96,792.65
6/18/2015	Al Kraus	Director	Sell	10,000	$5.78	$57,800.00
6/11/2015	Al Kraus	Director	Sell	10,000	$6.29	$62,900.00
6/4/2015	Al Kraus	Director	Sell	10,000	$6.30	$63,000.00
5/28/2015	Al Kraus	Director	Sell	10,000	$6.32	$63,200.00
11/17/2014	Al Kraus	Director	Sell	50,000	$0.23	$11,500.00
11/10/2014	Al Kraus	Director	Sell	50,000	$0.23	$11,500.00
11/3/2014	Al Kraus	Director	Sell	50,000	$0.23	$11,500.00
10/27/2014	Al Kraus	Director	Sell	100,000	$0.24	$24,000.00
10/10/2014	James T Gunton	Director	Sell	1,240,762	$0.24	$297,782.88
10/6/2014	Al Kraus	Director	Sell	50,000	$0.23	$11,500.00
9/29/2014	Al Kraus	Director	Sell	50,000	$0.23	$11,500.00
9/25/2014	Al Kraus	Director	Sell	41,500	$0.23	$9,545.00
9/22/2014	Al Kraus	Director	Sell	8,500	$0.23	$1,955.00
9/15/2014	Al Kraus	Director	Sell	50,000	$0.23	$11,500.00
9/12/2014	James T Gunton	Director	Sell	30,450	$0.24	$7,308.00
9/8/2014	Al Kraus	Director	Sell	50,000	$0.23	$11,500.00
9/5/2014	James T Gunton	Director	Sell	100,000	$0.24	$24,000.00
9/2/2014	Al Kraus	Director	Sell	50,000	$0.25	$12,500.00
9/2/2014	Kathleen P Bloch	CFO	Buy	65,000	$0.23	$14,950.00
8/28/2014	James T Gunton	Director	Sell	214,387	$0.24	$51,452.88
8/27/2014	James T Gunton	Director	Sell	1,360,000	$0.24	$326,400.00
8/25/2014	Al Kraus	Director	Sell	100,000	$0.25	$25,000.00
8/18/2014	Al Kraus	Director	Sell	100,000	$0.27	$27,000.00
8/11/2014	Al Kraus	Director	Sell	100,000	$0.28	$28,000.00
8/4/2014	Al Kraus	Director	Sell	50,000	$0.24	$12,000.00
7/21/2014	Al Kraus	Director	Sell	50,000	$0.24	$12,000.00
7/10/2014	Al Kraus	Director	Sell	50,000	$0.24	$12,000.00
7/7/2014	Al Kraus	Director	Sell	50,000	$0.24	$12,000.00
6/23/2014	Al Kraus	Director	Sell	50,000	$0.23	$11,500.00
6/18/2014	Al Kraus	Director	Sell	50,000	$0.24	$12,000.00
5/20/2014	Kathleen P Bloch	CFO	Buy	110,000	$0.24	$26,400.00
9/4/2012	Phillip P Chan	CEO	Buy	190,000	$0.13	$24,700.00

(Data available from 1/1/2013 forward)

Cytosorbents (NASDAQ CTSO) News Headlines

Source:

Date	Headline
	Cytosorbents Co. (CTSO) Expected to Post Earnings of -$0.13 Per Share www.americanbankingnews.com - April 24 at 3:10 PM
	Cytosorbents (CTSO) PT Set at $12.00 by Maxim Group www.americanbankingnews.com - April 24 at 12:14 PM
	CytoSorbents Enrolls First Patient into Pivotal US REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac ... www.prnewswire.com - April 24 at 8:46 AM
	BRIEF-Cytosorbents Enrolls First Patient Into Pivotal US Refresh 2-AKI Trial www.reuters.com - April 24 at 8:46 AM
	CytoSorbents Enrolls First Patient into Pivotal U.S. REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac Surgery finance.yahoo.com - April 24 at 8:46 AM
	Form 4 Cytosorbents Corp For: Apr 17 Filed by: BLOCH KATHLEEN P. www.streetinsider.com - April 19 at 8:46 AM
	Maxim Group Analysts Give Cytosorbents (CTSO) a $10.00 Price Target www.americanbankingnews.com - April 17 at 10:21 PM
	CytoSorbents to Meet With European Investors at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo and in Meetings in Frankfurt, Geneva and Zurich finance.yahoo.com - April 17 at 9:08 AM
	Cytosorbents (CTSO) Earns Buy Rating from B. Riley www.americanbankingnews.com - April 14 at 1:27 PM
	Cytosorbents (CTSO) Given a $13.00 Price Target by HC Wainwright Analysts www.americanbankingnews.com - April 12 at 8:29 PM
	Cytosorbents (CTSO) PT Raised to $12.00 at Maxim Group www.americanbankingnews.com - April 12 at 8:29 PM
	Cytosorbents (CTSO) Rating Increased to Hold at ValuEngine www.americanbankingnews.com - April 9 at 11:35 AM
	Cytosorbents Co. (CTSO) Expected to Post Quarterly Sales of $4.56 Million www.americanbankingnews.com - April 9 at 2:20 AM
	Cytosorbents (CTSO) Downgraded to "Sell" at ValuEngine www.americanbankingnews.com - April 8 at 12:54 PM
	Analysts Anticipate Cytosorbents Co. (CTSO) to Announce -$0.13 Earnings Per Share www.americanbankingnews.com - April 7 at 5:22 PM
	Form 4 Cytosorbents Corp For: Feb 21 Filed by: BLOCH KATHLEEN P. www.streetinsider.com - April 6 at 9:00 AM
	Cytosorbents Co. (CTSO) CFO Kathleen P. Bloch Sells 10,000 Shares www.americanbankingnews.com - April 5 at 10:20 PM
	Cytosorbents Co. (CTSO) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - April 5 at 1:37 AM
	CytoSorbents Refinances Existing Debt with New $15 Million Debt Facility with Bridge Bank finance.yahoo.com - April 4 at 8:51 AM
	ValuEngine Upgrades Cytosorbents (CTSO) to Buy www.americanbankingnews.com - April 4 at 12:02 AM
	Cytosorbents (CTSO) Upgraded at ValuEngine www.americanbankingnews.com - March 30 at 1:04 PM
	Cytosorbents (CTSO) Stock Rating Reaffirmed by HC Wainwright www.americanbankingnews.com - March 29 at 10:16 PM
	-$0.13 EPS Expected for Cytosorbents Corp (CTSO) This Quarter www.americanbankingnews.com - March 21 at 5:18 PM
	CTSO: Q4 2017 Update: Q4 / FY Product Sales +64% / 63%, Product Margin Jumps 900bp. FDA Pivotal Study Underway finance.yahoo.com - March 19 at 4:52 PM
	Insider Selling: Cytosorbents Corp (CTSO) CFO Sells 11,176 Shares of Stock www.americanbankingnews.com - March 19 at 1:35 PM
	CytoSorbents to Present at the 38th Annual Cowen Healthcare Conference finance.yahoo.com - March 12 at 12:10 PM
	Cytosorbents Corp (CTSO) Receives Average Recommendation of "Buy" from Brokerages www.americanbankingnews.com - March 11 at 1:38 AM
	BRIEF-Cytosorbents Achieves Record Revenue And Product Sales Growth In 2017 www.reuters.com - March 10 at 5:58 PM
	Cytosorbents (CTSO) Given a $12.00 Price Target by Maxim Group Analysts www.americanbankingnews.com - March 10 at 5:10 PM
	Cowen Reiterates "$9.00" Price Target for Cytosorbents (CTSO) www.americanbankingnews.com - March 10 at 12:30 AM
	Cytosorbents (CTSO) PT Set at $14.00 by HC Wainwright www.americanbankingnews.com - March 9 at 7:30 PM
	Cytosorbents (CTSO) Releases Earnings Results, Misses Expectations By $0.01 EPS www.americanbankingnews.com - March 9 at 12:38 AM
	CytoSorbents Achieves Record Revenue and Product Sales Growth in 2017 finance.yahoo.com - March 8 at 6:05 PM
	FY2017 Earnings Forecast for Cytosorbents Corp (CTSO) Issued By B. Riley www.americanbankingnews.com - March 7 at 7:26 AM
	Head-To-Head Survey: Harvard Bioscience (HBIO) and Cytosorbents (CTSO) www.americanbankingnews.com - March 7 at 1:16 AM
	Zacks: Brokerages Expect Cytosorbents Corp (CTSO) to Post -$0.10 Earnings Per Share www.americanbankingnews.com - March 4 at 1:32 PM
	Cytosorbents (CTSO) to Release Earnings on Thursday www.americanbankingnews.com - March 2 at 9:30 AM
	CytoSorbents to Report Fiscal 2017 Operating and Financial Results finance.yahoo.com - March 1 at 8:40 AM
	CytoSorbents to Participate at the BTIG Healthcare Conference finance.yahoo.com - February 26 at 8:44 AM
	$4.57 Million in Sales Expected for Cytosorbents Corp (CTSO) This Quarter www.americanbankingnews.com - February 17 at 2:28 AM
	Zacks: Brokerages Expect Cytosorbents Corp (CTSO) Will Post Earnings of -$0.10 Per Share www.americanbankingnews.com - February 15 at 9:12 PM
	CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia - PR Newswire (press release) www.prnewswire.com - February 15 at 8:13 AM
	CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia finance.yahoo.com - February 15 at 8:13 AM
	Cytosorbents Corp (CTSO) Given Average Recommendation of "Buy" by Brokerages www.americanbankingnews.com - February 14 at 1:28 AM
	Cytosorbents (CTSO) vs. Nanosphere (NSPH) Financial Analysis www.americanbankingnews.com - February 11 at 1:18 PM
	Analyzing Pacific Biosciences of California (PACB) and Cytosorbents (CTSO) www.americanbankingnews.com - February 8 at 7:02 PM
	CytoSorbents to Present at the 20th Annual BIO CEO & Investor Conference finance.yahoo.com - February 6 at 9:32 AM
	New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative ... - PR Newswire (press release) www.prnewswire.com - February 3 at 4:05 PM
	New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb® Blood Purification finance.yahoo.com - February 1 at 9:39 AM
	-$0.10 Earnings Per Share Expected for Cytosorbents Corp (CTSO) This Quarter www.americanbankingnews.com - January 29 at 9:14 PM

Cytosorbents (NASDAQ:CTSO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Cytosorbents (NASDAQ:CTSO) Income Statement, Balance Sheet and Cash Flow Statement

Cytosorbents (NASDAQ CTSO) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff